 Cookies help identify the right message.

We would like to use anonymous analytics cookies to help improve our website experience. View our cookie policy.

Skip to content
Pipeline Investors News Join us Contact

Contact Us

  • +44 [0] 20 4551 8888
  • contact@tangramtx.com
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X
Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.
  • About[+]
    • About[+]
      • Why Tangram?Explore more about how and why Tangram Therapeutics exists.
      • LeadershipDiscover the people leading the way in relentless medicine discovery.
  • Pipeline
  • Our science[+]
    • Our Science[+]
      • Our ApproachWe reduce the risks of making impactful medicine a reality.
      • LLibraConnecting extensive data and information with AI, powering GalOmic drug discovery.
      • GalOmicEnabling the generation of Tangram Therapeutics' potent and long-acting RNAi medicines.
  • Investors
  • News
  • Join us
  • Contact
Menu
Press release

Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

30 March 2026

  • Press release

COVID-19 Project Update

Dec 8, 2020

  • Press release

Interim Results for six months ended 31 July 2020

Oct 12, 2020

  • Press release

Appointment of Ali Mortazavi as CEO

Oct 12, 2020

  • Press release

Notice of Interim Results

Oct 5, 2020

  • Press release

Expansion of Scientific Advisory Board

Sep 28, 2020

  • Press release

Exercise of Broker Option and Total Fundraise

Jul 14, 2020

  • Press release

Exercise of Broker Option

Jul 9, 2020

  • Press release

Result of Retail Offer

Jul 8, 2020

  • Press release

Retail Offer

Jul 7, 2020

  • Press release

Fundraise of up to £12.4 million

Jul 7, 2020

  • Press release

Collaboration with Galapagos

Jun 10, 2020

  • Press release

Expansion into RNAi and creation of SAB

May 28, 2020

  • Press release

COVID-19 update: experimental testing initiated with WuXi AppTec

May 18, 2020

  • Press release

e-therapeutics to present at Shares Investor Evening

May 15, 2020

  • Press release

Appointment of Chief Business Officer

Apr 2, 2020

  • Press release

Notice of Annual General Meeting and Annual Report

Mar 31, 2020

  • Press release

Anti-viral drug discovery initiative

Mar 23, 2020

  • Press release

Results for the year ended 31 January 2020

Mar 17, 2020

  • Press release

Notification of Full Year Results Date

Mar 11, 2020

  • Press release

Board Changes and Placing

Feb 11, 2020

  • Press release

Half-year Report

Oct 7, 2019

  • Press release

e-therapeutics to work with top pharma company

Aug 13, 2019

  • Press release

Extends Research Collaboration with Novo Nordisk

Aug 1, 2019

  • Press release

Full Year Results

Mar 5, 2019

RELENTLESS
CREATIVITY

London HQ

  • Floor 4, 4 Kingdom Street
    Paddington Central London W2 6BD

[LOCAL TIME]

Company

  • About
  • Our Approach
  • Pipeline
  • Investors
  • News
  • Careers
  • Leadership
  • Contact

© 2026 Tangram Therapeutics. Brand and website by UnitedUs. V9.3

  • Press Release Sign Up
  • Sitemap
  • Accessibility
  • Privacy
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X

OUR TRANSFORMATION INTO TANGRAM

Pioneering advancements in drug development takes steadfast persistence. A ceaseless evolution of understanding and innovation. That’s why E-Therapeutics has transformed into Tangram Therapeutics. The new brand embodies the expedited exploration needed to unlock life-transforming RNAi medicines faster. Breaking conventions of slow science, Tangram makes sense of patterns to find new answers. Our transformation into Tangram reveals the robust focus necessary for relentless medicine discovery.

Discover our new identity